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Introduction
It is a distinct privilege to be inducted into the Academia Nacional de
Agronomia y Veterinaria and to become a member of this esteemed Academy. I
am extremely grateful for this honor and to the academy members for nominating
me and bestowing this honor on me.
My fortuitous journey to Argentina began 22 years ago in 1987 when I was
invited by Dr Alejandro Schudel, then Director of Virology at INTA, Castelar, to
visit Argentina to initiate a joint collaboration. The topic was «Rotavirus infections
in calves: development and evaluation of maternal vaccines for passive immunity
in calves».  Passive immunity and enteric viral infections in swine and cattle
were two of my major research interests at the Food Animal Health Research
Program, Ohio Agricultural Research and Development Center (OARDC), The
Ohio State University (OSU) in the USA. At the time, calf diarrhea was a critical
problem in both beef and dairy calves, but the major causes were undefined.
Our goals were first to identify the dominant pathogens in the field associated
with calf diarrhea and deaths and second to develop methods for their prevention
and control. To accomplish these goals, we addressed each of the following
key questions in collaborative studies conducted in Argentina (INTA) and the
USA (OARDC/The Ohio State University).
What is the major calf diarrhea pathogen?
In the dairy and beef industries in the USA, neonatal diarrhea causes
economical losses of approximately $500 million per year. In studies conducted
with a visiting scholar, Dr Alejandro Lucchelli from INTA (Castelar, Argentina), we
found that group A rotaviruses are the most frequently detected in cases of calf
diarrhea and almost 100% of cattle have antibodies to bovine rotavirus (BRV). In
Argentina, Biochemist Garaicoechea in our collaborators’ INTA lab (Drs Parreno
and Fernandez) demonstrated that BRV is associated with 62.5% of calf diarrhea
cases. In their studies, she and Dr Costantini determined that BRV was the
most frequently detected diarrhea pathogen in beef and dairy herds during a 10-
year study period (1994-2003).
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What are the dominant rotavirus P (VP4) and G (VP7) serotypes in calves in
the USA and Argentina?
Besides diarrhea in young animals, rotaviruses are also the leading
cause of severe gastroenteritis in infants and young animals worldwide with
about 600,000 deaths in infants per year, mostly in developing countries.
Rotaviruses possess a triple-shelled capsid with a dsRNA genome. Like
influenza viruses, they have a dual serotype specificity based on the two outer
capsid proteins, VP4 (P type) and VP7 (G type), each of which elicit neutralizing
antibodies.  To develop effective stategies to control rotavirus diarrhea, it is
essential to know which are the dominant rotavirus P (VP4) and G (VP7) serotypes
in calves essential for inclusion in rotavirus vaccines and if they are the same in
the USA and Argentina. Joint studies revealed common rotavirus serotypes
circulating in the USA and Argentina. Surprisingly, in both countries, whereas
G6P[5] was the prevalent strain in beef herds, a different serotype, G10P[11]
was the dominant strain in dairy herds. Thus both of these G and P types are
needed for effective BRV vaccines to be used in beef and dairy calves.
How can BRV vaccines be designed to protect young calves from rotavirus
diarrhea?
1) Live oral vaccines for active immunity. Several factors influenced our
strategies for development of rotavirus vaccines. Both in Argentina and the
USA, calves under 3 weeks of age are most susceptible to rotavirus infection
with peak diarrhea and deaths at 6-14 days of age. Thus there is not
adequate time for calves to develop active immunity even if vaccines are
given at birth. Also because rotavirus infections are widespread, most cows
have antibodies to rotavirus in serum and mammary secretions. Interference
by pre-existing maternal antibodies causes inconsistent results for active
immunization of newborn calves using live oral rotavirus vaccines.
2) Maternal vaccines to provide passive immunity to suckling or colostrum-
fed calves.
Immunoglobulin IgG1 is selectively transported from serum into the
mammary gland with secretion into colostrum and milk. The IgG1 is
selectively transferred via the neonatal Fc receptor (FcRn) into the mammary
gland, then secreted into colostrum and milk. Thus parenteral vaccination
of pregnant cows represents an effective strategy to increase colostral and
milk IgG1 antibodies. Importantly since most cows have antibodies to
rotavirus, maternal vaccines were needed only to boost the pre-existing
serum and colostrum antibody titers.
In cattle, no antibodies are transferred across the placenta. Thus, calves
are born without circulating antibodies (agammaglobulinemic) which they
acquire only via colostrum after suckling. A striking finding of both our
studies and those of our Argentine collaborators (Drs Parreno and
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Fernandez) was that after transfer of these maternal IgG1 antibodies via
suckling to the calf intestine and uptake into blood, these antibodies are
then transiently resecreted back into the intestine thereby providing both
systemic and local protection.
How can we design rotavirus vaccines to enhance serum IgG1 antibodies in
pregnant cows leading to increased colostrum/milk antibodies to rotavirus
and passive immunity in calves?
1) Dairy Cattle; colostrum supplemented calves. We initially investigated
rotavirus vaccination approaches for pregnant dairy cattle. Observations by
Watson and Lascelles in Australia in 1975 revealed new strategies to increase
antibody secreting cells in the mammary gland to prevent mastitis in dairy cattle.
They proposed that antigen given intramuscularly (IM) with oil adjuvant near
involution seeded memory B cells to the mammary gland. Subsequent boosting
with antigen via intramammary infusion (IMm) in oil adjuvant during the dry
period led to extremely high titers of IgG1 antibodies in serum with their
subsequent transport to the mammary gland and secretion into colostrum and
milk. We successfully adapted these approaches for live attenuated and
inactivated rotavirus vaccines and produced exceptionally high antibody titers in
mammary secretions. However a commercial attenuated rotavirus vaccine given
IM without adjuvant at a 4 log lower dose than the IM+IMm vaccine failed to
significantly increase the antibody titers in mammary secretions above titers in
non-vaccinated cows. Our results indicate that the dose, route of vaccination
and use of oil adjuvants are critical factors for the success of maternal rotavirus
vaccines.
Another important observation was that as little as 1% colostrum
supplements from the IM+IMm vaccinated cows provided almost complete
passive protection to colostrum-deprived dairy calves against rotavirus challenge
(diarrhea and shedding) at 20-25 hrs of age. Colostrum from the IM vaccinated
or non-vaccinated control cows did not provide passive protection when fed at
similar levels. This protection was correlated with the IgG1 and neutralizing
antibody titer to rotavirus in the colostrum.
In collaboration with a visiting scholar, Dr Fernando Fernandez from INTA,
we next bioengineered and tested a new generation of rotavirus vaccines.  The
virus-like particle (VLP) and core-like particle (CLP) recombinant vaccines were
produced in a bacculovirus expression system by co-expression of multiple
rotavirus genes encoding the core and inner capsid (VP2/VP6 CLP) or also the
outer capsid neutralizing antigens (VP2/VP4/VP6/VP7 VLP). The rationale for
use of such vaccines is that they are safe and noninfectious but they retain the
structure and immunogenicity of live rotavirus. Since no harsh inactivating agents
are needed like those routinely used to inactivate vaccines, the neutralizing
antigens are better preserved. Both VLP and CLP vaccines significantly
enhanced IgG1 antibodies in mammary secretions, but only the VLPs with VP4
and VP7 increased the neutralizing antibody titers. Both CLP and VLP vaccines
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and an inactivated rotavirus vaccine at least partially passively protected calves
against rotavirus diarrhea. However only the VLP vaccine was effective in
protecting calves against rotavirus diarrhea and shedding, emphasizing the
added contribution of neutralizing antibodies. The finding that the CLP vaccine
based on VP6 that induces high titer cross-reactive, but non-neutralizing
antibodies provided moderate levels of passive protection suggests that vaccines
based on VP6 may also elicit some protection.
2) Beef cattle; naturally suckled calves. In further collaborative studies with
Drs Schudel and Fernadez at INTA in Argentina, we initiated a project to develop
a maternal rotavirus vaccine for use in beef cows to passively protect their
suckling calves. This was a joint effort with Argentine industry (Biogenesis-
BAGO), national/international institutions (INTA, OARDC/OSU, Fulbright) and
the private sector (field test vaccines at Estancia La Angelica with the collaboration
of Ing Agr Romat). A factor that expedited this collaboration was my receiving a
short-term Fulbright Fellowship enabling me to conduct a phase of this research
in Argentina, including a visit to La Angelica during the field trials.  Building on
our prior experience with maternal rotavirus vaccines, we designed a chemically-
inactivated rotavirus vaccine containing the dominant rotavirus serotypes (G6P[5],
G10P[11])  administered in oil adjuvant. This vaccine successfully controlled
rotavirus diarrhea in the field trials and was then produced commercially in
Argentina. Our dramatic results showed decreased diarrhea and deaths after
introduction of the vaccine in Argentina and demonstrated the feasibility and
effectiveness of such joint ventures in solving a major disease problem in the
field.
Do high titer maternal antibodies in colostrum passively protect neonates
but suppress active antibody responses to rotavirus?
It is recognized that high titer maternal antibodies interfere with live oral
vaccines. However the mechanisms for this immunosuppression are unclear
as are the means to overcome maternal antibody suppression of oral vaccines
or induction of active antibody responses. A visiting scholar in my lab, Dr Parreno
from INTA initially investigated this question using germfree piglets fed
homologous colostrum/milk antibodies from sows immunized with human
rotavirus. Advantages to using the germfree piglet model to study immunity to
human rotavirus include: 1) They are the only animal model susceptible to
human rotavirus diarrhea and the gut lesions resemble those in human infants
permitting evaluation of protective immunity to virus challenge. 2) Extraneous
enteropathogens (rotaviruses) and maternal antibodies are absent so passive
or active immune responses to human rotavirus can be assessed. 3) The
piglet gastrointestinal physiology, size, milk diet and mucosal immune
responses are similar to human infants.
We found that high titer passive Abs provided partial protection post-primary
challenge, but suppressed active IgA gut Ab responses leading to reduced
protection post-secondary challenge (Post-Inoculation Day 21). Consequently
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multiple doses of live oral vaccines, as formulated for current licensed human
rotavirus vaccines, are needed to overcome the immunosuppression.
Unfortunately this increases vaccine costs, significantly impacting vaccine use
in developing countries where the need is greatest. We also used the germfree
piglet model to investigate active intestinal immune responses to human
rotavirus vaccines. Dr Ana Sadir, a visiting scholar from INTA with expertise in
viral immunology, greatly assisted us in these efforts.
In Argentina, Drs Parreno and colleagues conducted similar studies in
calves receiving homologous colostrum from cows vaccinated IM 3X with a live
BRV vaccine. Passive colostrum Abs suppressed active Ab responses in calves
in a dose-dependent manner. The lowest numbers of Ab secreting cells (all
isotypes) were in the IM 3x colostrum fed calves which had the highest serum
IgG1 Ab titers. These findings supported and extended the results seen in the
germfree piglets. They confirmed that additional approaches (adjuvants, vaccine
design,etc) are needed to overcome this problem.
Do heterologous Abs (Llama VHH or chicken IgY) provide passive
protection without suppression of active antibody responses of neonatal
pigs, infants or
calves challenged with rotavirus?
In 2009 a new phase of the collaboration between INTA and OSU was
initiated to address the above question. Partial support for this project is provided
by a Fogarty International R03 competitive grant from the US National Institutes
of Health to Drs Saif, Parreno and Fernandez. Preliminary data generated by
Drs Garaicoechea, Parreno and colleagues indicated that the unique single
domain recombinant VHH antibodies derived from llamas and generated to
bovine rotavirus VP6 neutralized diverse rotavirus serotypes in vitro and passively
protected neonatal mice challenged  in vivo with murine rotavirus. Thus our
current focus is whether heterologous passive antibodies (llama VHH and
chicken IgY) will be less suppressive of active antibody responses to rotavirus.
Most critically, we will determine if VHH or chicken IgY antibodies against BRV
VP6 passively protect germfree piglets against rotavirus diarrhea as a model
for infants.
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As Marie Curie, the Nobel Prize winner said, «One never notes what has been
done; one can only see what remains to be done.»  It is gratifying to me that I
have been able to pursue my passion for science and to collaborate with and
mentor such talented and dedicated students and colleagues from Argentina.  I
hope that I have enriched their scientific knowledge and lives as much as they
have mine. I look forward to continuing to contribute to the human and veterinary
scientific communities, in the USA, Argentina and globally.
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